# Neonode Inc.: financial statements, quarterly

NEON · Nasdaq · CIK 87050 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/neon.md) · [Financials](/companies/neon/financials.md) · [Filings](/companies/neon/filings.md) · [Insiders](/companies/neon/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/neon/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.0](/filings/0001213900-23-084973.md) | [0.4 d](/filings/0001013762-25-000774.md) | [0.8](/filings/0001213900-25-043002.md) | [0.8](/filings/0001213900-25-075332.md) | [0.8](/filings/0001437749-25-033478.md) | [0.7 d](/filings/0001013762-25-000774.md) | [0.5](/filings/0001213900-25-043002.md) | [0.6](/filings/0001213900-25-075332.md) | [0.4](/filings/0001437749-25-033478.md) | [0.5 d](/filings/0001437749-26-008759.md) | [0.6](/filings/0001437749-26-016562.md) | [0.5](/filings/0001437749-26-027162.md) |
| Cost of revenue | $m | [0.2](/filings/0001213900-23-084973.md) | [0.0 d](/filings/0001013762-25-000774.md) | [0.0](/filings/0001213900-25-043002.md) | [0.0](/filings/0001213900-25-075332.md) | [0.0](/filings/0001437749-25-033478.md) | [0.1 d](/filings/0001437749-26-008759.md) | [0.0](/filings/0001437749-26-016562.md) | [0.0](/filings/0001437749-26-027162.md) | [0.0](/filings/0001437749-25-033478.md) | [0.0 d](/filings/0001437749-26-008759.md) | [0.0](/filings/0001437749-26-016562.md) | [0.0](/filings/0001437749-26-027162.md) |
| Gross profit | $m | [0.8](/filings/0001213900-24-094789.md) | [0.7 d](/filings/0001013762-25-000774.md) | [0.8](/filings/0001213900-25-043002.md) | [0.8](/filings/0001213900-25-075332.md) | [0.8](/filings/0001437749-25-033478.md) | [0.6 d](/filings/0001437749-26-008759.md) | [0.5](/filings/0001437749-26-016562.md) | [0.6](/filings/0001437749-26-027162.md) | [0.4](/filings/0001437749-25-033478.md) | [0.5 d](/filings/0001437749-26-008759.md) | [0.6](/filings/0001437749-26-016562.md) | [0.5](/filings/0001437749-26-027162.md) |
| Research and development | $m | [0.8](/filings/0001213900-24-094789.md) | [1.1 d](/filings/0001013762-25-000774.md) | [0.9](/filings/0001213900-25-043002.md) | [1.0](/filings/0001213900-25-075332.md) | [0.8](/filings/0001437749-25-033478.md) | [0.8 d](/filings/0001437749-26-008759.md) | [1.0](/filings/0001437749-26-016562.md) | [1.1](/filings/0001437749-26-027162.md) | [0.8](/filings/0001437749-25-033478.md) | [0.9 d](/filings/0001437749-26-008759.md) | [0.9](/filings/0001437749-26-016562.md) | [1.0](/filings/0001437749-26-027162.md) |
| Selling, general and administrative | $m | not reported | not reported | [0.4](/filings/0001213900-25-043002.md) | not reported | not reported | not reported | [0.2](/filings/0001213900-25-043002.md) | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(1.3)](/filings/0001213900-24-094789.md) | [(1.8) d](/filings/0001013762-25-000774.md) | [(1.9)](/filings/0001213900-25-043002.md) | [(1.8)](/filings/0001213900-25-075332.md) | [(1.2)](/filings/0001437749-25-033478.md) | [(1.7) d](/filings/0001437749-26-008759.md) | [(2.0)](/filings/0001437749-26-016562.md) | [(2.1)](/filings/0001437749-26-027162.md) | [13.8](/filings/0001437749-25-033478.md) | [(2.4) d](/filings/0001437749-26-008759.md) | [(2.1)](/filings/0001437749-26-016562.md) | [(2.3)](/filings/0001437749-26-027162.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001213900-24-094789.md) | [0.0 d](/filings/0001013762-25-000774.md) | [0.0](/filings/0001213900-25-043002.md) | [0.0](/filings/0001213900-25-075332.md) | [(0.0)](/filings/0001437749-25-033478.md) | [0.0 d](/filings/0001437749-26-008759.md) | [(0.0)](/filings/0001437749-26-016562.md) | [0.0](/filings/0001437749-26-027162.md) | [0.0](/filings/0001437749-25-033478.md) | [0.0 d](/filings/0001437749-26-008759.md) | [0.0](/filings/0001437749-26-016562.md) | [0.0](/filings/0001437749-26-027162.md) |
| Net income | $m | [(1.3)](/filings/0001213900-24-094789.md) | [(5.9) d](/filings/0001013762-25-000774.md) | [(2.1)](/filings/0001437749-25-033478.md) | [(1.7)](/filings/0001437749-25-033478.md) | [(1.1)](/filings/0001437749-25-033478.md) | [(1.6) d](/filings/0001437749-26-008759.md) | [(1.7)](/filings/0001437749-26-027162.md) | [(1.9)](/filings/0001437749-26-027162.md) | [14.2](/filings/0001437749-25-033478.md) | [(2.1) d](/filings/0001437749-26-008759.md) | [(1.9)](/filings/0001437749-26-027162.md) | [(2.1)](/filings/0001437749-26-027162.md) |
| Diluted EPS | $ per share | [(0.08)](/filings/0001213900-24-094789.md) | not reported | [(0.14)](/filings/0001213900-25-043002.md) | [(0.11)](/filings/0001213900-25-075332.md) | [(0.07)](/filings/0001213900-24-094789.md) | not reported | [(0.10)](/filings/0001213900-25-043002.md) | [(0.11)](/filings/0001213900-25-075332.md) | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.08)](/filings/0001213900-24-094789.md) | not reported | [(0.14)](/filings/0001213900-25-043002.md) | [(0.11)](/filings/0001213900-25-075332.md) | [(0.07)](/filings/0001437749-25-033478.md) | not reported | [(0.10)](/filings/0001437749-26-016562.md) | [(0.11)](/filings/0001437749-26-027162.md) | [0.85](/filings/0001437749-25-033478.md) | not reported | [(0.11)](/filings/0001437749-26-016562.md) | [(0.13)](/filings/0001437749-26-027162.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [18.5](/filings/0001213900-23-084973.md) | [16.2](/filings/0001013762-25-000774.md) | [14.3](/filings/0001213900-24-040663.md) | not reported | not reported | [16.4](/filings/0001437749-26-008759.md) | [15.0](/filings/0001213900-25-043002.md) | [13.2](/filings/0001213900-25-075332.md) | [11.6](/filings/0001437749-25-033478.md) | [25.4](/filings/0001437749-26-027162.md) | [23.2](/filings/0001437749-26-016562.md) | [21.3](/filings/0001437749-26-027162.md) |
| Current assets | $m | [24.5](/filings/0001213900-23-084973.md) | [18.6](/filings/0001013762-25-000774.md) | [16.6](/filings/0001213900-24-040663.md) | [15.1](/filings/0001213900-24-066356.md) | [19.6](/filings/0001213900-24-094789.md) | [17.7](/filings/0001437749-26-008759.md) | [16.3](/filings/0001213900-25-043002.md) | [14.4](/filings/0001213900-25-075332.md) | [32.2](/filings/0001437749-25-033478.md) | [26.3](/filings/0001437749-26-027162.md) | [24.4](/filings/0001437749-26-016562.md) | [22.4](/filings/0001437749-26-027162.md) |
| Total assets | $m | [24.8](/filings/0001213900-23-084973.md) | [19.0](/filings/0001013762-25-000774.md) | [16.9](/filings/0001213900-24-040663.md) | [15.2](/filings/0001213900-24-066356.md) | [19.6](/filings/0001213900-24-094789.md) | [18.4](/filings/0001437749-26-008759.md) | [17.0](/filings/0001213900-25-043002.md) | [15.1](/filings/0001213900-25-075332.md) | [32.8](/filings/0001437749-25-033478.md) | [26.9](/filings/0001437749-26-027162.md) | [24.9](/filings/0001437749-26-016562.md) | [23.6](/filings/0001437749-26-027162.md) |
| Current liabilities | $m | [1.8](/filings/0001213900-23-084973.md) | [1.8](/filings/0001013762-25-000774.md) | [1.9](/filings/0001213900-24-040663.md) | [1.9](/filings/0001213900-24-066356.md) | [1.6](/filings/0001213900-24-094789.md) | [1.6](/filings/0001437749-26-008759.md) | [2.1](/filings/0001213900-25-043002.md) | [2.2](/filings/0001213900-25-075332.md) | [5.9](/filings/0001437749-25-033478.md) | [2.2](/filings/0001437749-26-027162.md) | [2.1](/filings/0001437749-26-016562.md) | [2.1](/filings/0001437749-26-027162.md) |
| Total liabilities | $m | [1.8](/filings/0001213900-23-084973.md) | [1.9](/filings/0001013762-25-000774.md) | [1.9](/filings/0001213900-24-040663.md) | [1.9](/filings/0001213900-24-066356.md) | [1.6](/filings/0001213900-24-094789.md) | [1.9](/filings/0001437749-26-008759.md) | [2.4](/filings/0001213900-25-043002.md) | [2.4](/filings/0001213900-25-075332.md) | [6.0](/filings/0001437749-25-033478.md) | [2.2](/filings/0001437749-26-027162.md) | [2.1](/filings/0001437749-26-016562.md) | [2.9](/filings/0001437749-26-027162.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [23.0](/filings/0001213900-24-094789.md) | [17.2](/filings/0001437749-26-008759.md) | [15.0](/filings/0001437749-25-033478.md) | [13.3](/filings/0001437749-25-033478.md) | [18.0](/filings/0001437749-25-033478.md) | [16.4](/filings/0001437749-26-027162.md) | [14.6](/filings/0001437749-26-027162.md) | [12.7](/filings/0001437749-26-027162.md) | [26.8](/filings/0001437749-25-033478.md) | [24.7](/filings/0001437749-26-027162.md) | [22.8](/filings/0001437749-26-027162.md) | [20.8](/filings/0001437749-26-027162.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,785) d](/filings/0001213900-24-094789.md) | [(2,208) d](/filings/0001013762-25-000774.md) | [(1,915)](/filings/0001213900-25-043002.md) | [(1,220) d](/filings/0001213900-25-075332.md) | [(1,294) d](/filings/0001437749-25-033478.md) | [(1,163) d](/filings/0001437749-26-008759.md) | [(1,360)](/filings/0001437749-26-016562.md) | [(1,750) d](/filings/0001437749-26-027162.md) | [(1,527) d](/filings/0001437749-25-033478.md) | [(5,617) d](/filings/0001437749-26-008759.md) | [(2,106)](/filings/0001437749-26-016562.md) | [(1,896) d](/filings/0001437749-26-027162.md) |
| Capital expenditure | $k | [22.0](/filings/0001213900-24-094789.md) | [65.0 d](/filings/0001013762-25-000774.md) | not reported | not reported | [0.0 d](/filings/0001437749-25-033478.md) | [0.0 d](/filings/0001437749-26-008759.md) | [40.0](/filings/0001437749-26-016562.md) | [(25.0) d](/filings/0001437749-26-027162.md) | [75.0 d](/filings/0001437749-25-033478.md) | [1.0 d](/filings/0001437749-26-008759.md) | [13.0](/filings/0001437749-26-016562.md) | [1.0 d](/filings/0001437749-26-027162.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.0](/filings/0001213900-22-070864.md) | [0.0](/filings/0001213900-23-038310.md) | [0.0](/filings/0001213900-23-065311.md) | [0.0](/filings/0001213900-23-084973.md) | [0.0](/filings/0001213900-24-040663.md) | [0.0](/filings/0001213900-24-066356.md) | [0.0](/filings/0001213900-24-094789.md) | [0.0](/filings/0001213900-25-043002.md) | [15.4](/filings/0001213900-25-075332.md) | [0.0](/filings/0001213900-24-094789.md) | [0.0](/filings/0001213900-25-043002.md) | [16.8](/filings/0001213900-25-075332.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 16,782,922 at 2026-08-10, from the cover of the [10-Q filed 2026-08-12](/filings/0001437749-26-027162.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:20 ET. No prices; not investment advice.